Ultrasonography (US) is extensively used in the diagnosis of prostate cancer; but with its disadvantages of poor sensitivity and specificity, frequently causes underdiagnosis, and over 50% of the results of transrectal ultrasound (TRUS)-guided biopsy fail to accord with those of surgical pathology.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In addition to contrast-enhanced ultrasound and real-time elastography, various new ultrasonic techniques have been developed nowadays, such as prostate histoscanning, brachytherapy template-guided 3-dimensional mapping biopsy (3DMB), and MRI/US fusion. Prostate histoscanning is an ultrasound-based technology that uses computer-aided analysis to identify and characterize the foci of prostate cancer. 3DMB, involving the whole gland, has an even higher accuracy. MRI/US fusion integrates the advantages of pre-interventional MRI with those of peri-interventional ultrasonography, and offers high-resolution images and convenient puncturing. Constant development of ultrasonography will continue to add to its clinical application value.
Zhang YY, Hu B, Chen L. Are you the author?
Reference: Zhonghua Nan Ke Xue. 2015 Jan;21(1):78-81.
Article in Chinese.